Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.066 CHF
10.45 M CHF
157.63 M CHF
11.12 M
About BASILEA N
Sector
CEO
David Veitch
Headquarters
Allschwil
Website
Founded
2000
ISIN
CH0011432447
FIGI
BBG006M6Z321
Basilea Pharmaceutica AG engages in the development and commercialization of pharmaceutical products. Its products include antifungals and antibiotics. The company was founded on October 17, 2000, and is headquartered in Allschwil, Switzerland.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of PK5 is 40.603 CHF — it has decreased by −2.19% in the past 24 hours. Watch BASILEA PHARMACEU stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BX exchange BASILEA PHARMACEU stocks are traded under the ticker PK5.
PK5 stock has fallen by −4.68% compared to the previous week, the month change is a −9.71% fall, over the last year BASILEA PHARMACEU has showed a 14.41% increase.
We've gathered analysts' opinions on BASILEA PHARMACEU future price: according to them, PK5 price has a max estimate of 100.00 CHF and a min estimate of 52.00 CHF. Watch PK5 chart and read a more detailed BASILEA PHARMACEU stock forecast: see what analysts think of BASILEA PHARMACEU and suggest that you do with its stocks.
PK5 stock is 2.24% volatile and has beta coefficient of 1.21. Track BASILEA PHARMACEU stock price on the chart and check out the list of the most volatile stocks — is BASILEA PHARMACEU there?
Today BASILEA PHARMACEU has the market capitalization of 484.85 M, it has decreased by −3.29% over the last week.
Yes, you can track BASILEA PHARMACEU financials in yearly and quarterly reports right on TradingView.
BASILEA PHARMACEU is going to release the next earnings report on Feb 18, 2025. Keep track of upcoming events with our Earnings Calendar.
PK5 earnings for the last half-year are 1.61 CHF per share, whereas the estimation was 1.17 CHF, resulting in a 37.61% surprise. The estimated earnings for the next half-year are 2.48 CHF per share. See more details about BASILEA PHARMACEU earnings.
BASILEA PHARMACEU revenue for the last half-year amounts to 76.30 M CHF, despite the estimated figure of 106.10 M CHF. In the next half-year revenue is expected to reach 125.93 M CHF.
PK5 net income for the last half-year is 20.74 M CHF, while the previous report showed −21.39 M CHF of net income which accounts for 196.95% change. Track more BASILEA PHARMACEU financial stats to get the full picture.
No, PK5 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 19, 2024, the company has 147.00 employees. See our rating of the largest employees — is BASILEA PHARMACEU on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. BASILEA PHARMACEU EBITDA is −4.99 M CHF, and current EBITDA margin is 14.39%. See more stats in BASILEA PHARMACEU financial statements.
Like other stocks, PK5 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade BASILEA PHARMACEU stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So BASILEA PHARMACEU technincal analysis shows the sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating BASILEA PHARMACEU stock shows the sell signal. See more of BASILEA PHARMACEU technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.